AI summary · may contain errors
A single infusion of amrecibart or cenvacibart reduced adjudicated venous thromboembolism by day 14 after PICC placement, with 20% vs 43% on placebo.
Moving in Journal of the American Society of Nephrology, Clinical Infectious Diseases, Kidney International, Journal of the American College of Cardiology and The Lancet Haematology.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
A single infusion of amrecibart or cenvacibart reduced adjudicated venous thromboembolism by day 14 after PICC placement, with 20% vs 43% on placebo.
AI summary · may contain errors
In a randomized trial of transfemoral TAVR in China, single-ProGlide closure was noninferior to double-ProGlide for VARC-3 access-site or access-related vascular complications (13.1% vs 15.1%).
Journals this month
Topics moving, week to 17 Nov 2026
By field